Currently, Adaptimmune Therapeutics Plc ADR [ADAP] is trading at $1.71, up 17.12%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ADAP shares have gain 6.21% over the last week, with a monthly amount glided 46.15%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates. In a post published today on Yahoo Finance, U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on March 24, 2023, when Bryan Garnier initiated its Buy rating and assigned the stock a price target of $3.60. Previously, Guggenheim upgraded its rating to Buy on January 03, 2023, and kept the price target unchanged to $5. On November 09, 2022, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. Barclays started tracking the stock assigning a Underweight rating and suggested a price target of $4 on May 28, 2021. Mizuho initiated its recommendation with a Neutral and recommended $3 as its price target on April 22, 2020. Guggenheim downgraded its rating to Neutral for this stock on August 02, 2019. In a note dated May 31, 2019, ROTH Capital initiated an Buy rating.
This stock has fluctuated between a low of $0.42 and a high of $1.79 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $1.71 at the most recent close of the market. An investor can expect a potential return of 75.44% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
Trailing Twelve Months sales for Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] were 71.57M which represents 4.74% growth. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -1.64%, Pretax Profit Margin comes in at -1.3%, and Net Profit Margin reading is -1.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -1.0 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5500 points at the first support level, and at 1.3900 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8100, and for the 2nd resistance point, it is at 1.9100.
Adaptimmune Therapeutics Plc ADR [ADAP] reported earnings per share of -$0.2 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.12/share, meaning a difference of -$0.08 and a surprise factor of -66.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.12 per share as compared to estimates of -$0.13 per share, a difference of $0.01 representing a surprise of 7.70%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] is 2.92. Also, the Quick Ratio is 2.92, while the Cash Ratio stands at 1.2. Considering the valuation of this stock, the price to sales ratio is 5.42, the price to book ratio is 4.40.
Transactions by insiders
Recent insider trading involved Rawcliffe Adrian, Chief Executive Officer, that happened on Jan 17 ’24 when 30080.0 shares were sold. Chief Operating Officer, Bertrand William C JR completed a deal on Jan 17 ’24 to sell 18908.0 shares. Meanwhile, Chief Medical Officer Norry Elliot sold 18276.0 shares on Jan 17 ’24.
